Guangdong Hengrui Pharmaceutical Co., Ltd
Clinical trials sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd, explained in plain language.
A subsidiary of Jiangsu Hengrui Pharmaceuticals, involved in the development and manufacturing of pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot for eczema shows promise in early trial Results expected Sep 2026 (estimated)
- New inhaled powder for COPD heads into first human tests Results expected Sep 2026 (estimated)
- New inhaler hope for COPD patients in early trial Results expected Oct 2026 (estimated)
- New injection could tame seasonal allergy symptoms for those failed by standard treatments Results expected Dec 2026 (estimated)
- Can an experimental injection clear stubborn psoriasis? a new trial aims to find out. Results expected Dec 2026 (estimated)
-
New shot could tame tough eczema in large trial
Disease control CompletedThis Phase 3 trial tests an experimental injection called SHR-1819 in 652 adults with moderate to severe atopic dermatitis (eczema). Half get the drug, half get a placebo. The main goal is to see if it improves skin rash and itch after 16 weeks. If it works, it may offer a new wa…
Phase 3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new drug shrink nasal polyps and restore smell?
Disease control CompletedThis phase 2 trial is testing whether an experimental drug called SHR-1905 can reduce nasal polyps and improve symptoms like congestion and loss of smell in people with chronic sinusitis. Participants will receive either the drug or a placebo alongside their usual nasal spray tre…
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug aims to tame severe eczema in kids and teens
Disease control CompletedThis study tests an experimental drug called SHR-1819 in children and adolescents aged 6 to 17 with moderate-to-severe atopic dermatitis (a type of eczema). The main goal is to check the drug's safety and how the body processes it. Researchers will also look at changes in skin-re…
Phase 1/2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New oral drug HRS-9813 takes first step against scarred lungs
Disease control CompletedThis Phase 1 trial tests the safety and how the body handles HRS-9813, an experimental oral drug for idiopathic pulmonary fibrosis (a lung-scarring disease). Healthy volunteers aged 18-45 take multiple doses to measure side effects and drug levels in the blood. The study does not…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New arthritis drug candidate SHR-3045 tested in healthy volunteers
Disease control CompletedThis Phase 1 study tested a single injection of SHR-3045 in 16 healthy adults to see if it is safe and how the body processes it. The drug is being developed as a potential treatment for rheumatoid arthritis, an autoimmune disease that causes joint pain and swelling. Because this…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New rheumatoid arthritis drug candidate passes first safety check in healthy volunteers
Disease control CompletedThis early-stage trial tested the safety of a new drug called SHR-3045 in 40 healthy adults. The study was randomized, double-blind, and placebo-controlled, meaning some participants got the drug and some got a dummy shot. The main goal was to see if the drug causes any side effe…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New psoriasis drug SHR-1139 enters first human trials
Disease control CompletedThis early-stage trial tests a new drug called SHR-1139 in healthy volunteers and people with moderate-to-severe plaque psoriasis. The main goal is to check safety and how the body handles the drug. A total of 64 participants will receive either the drug or a placebo, with doses …
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New shot shows promise for teen asthma
Disease control CompletedThis study tested a single injection of a new drug called SHR-1905 in 9 teenagers with asthma. The goal was to see how the drug moves through the body, if it is safe, and if it helps control asthma. Participants were aged 12 to 17, had asthma for at least 6 months, and were on st…
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New shot for lupus passes first safety check in small study
Disease control CompletedThis early-stage study tested an experimental drug called SHR-2173 in 30 adults with systemic lupus erythematosus (SLE). The drug was given as multiple injections under the skin. The main goal was to see if it is safe and tolerable, and to measure how the body processes it. This …
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New COPD inhaler drug enters human safety testing
Symptom relief CompletedThis early-stage study tests a new inhaled drug called HRS-9821 in 160 people. First, healthy volunteers get a single dose to check safety. Then, people with COPD receive multiple doses. The main goal is to see what side effects occur and how the drug moves through the body. This…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New shot could tame hay fever misery
Symptom relief CompletedThis study tests an injection called SHR-1819 in 100 adults with seasonal allergic rhinitis (hay fever). Participants will receive either the drug or a placebo to see if it reduces daily nasal symptoms like sneezing and stuffiness. The trial is double-blind, meaning neither patie…
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
New asthma inhaler passes first safety check in small study
Symptom relief CompletedThis early-stage trial tested an experimental drug called SHR-4597, given as an inhaled powder, in 62 healthy volunteers and people with asthma. The main goal was to see if it is safe and tolerable. The study gave single doses to healthy people and multiple doses over several day…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New pill shows promise for stubborn cough that Won't quit
Symptom relief CompletedThis study tested an experimental drug called HRS-2261 in 97 adults with refractory chronic cough—a persistent cough that doesn't respond to usual treatments. Participants took the drug or a placebo for 4 weeks to see if it reduced cough severity and improved quality of life. The…
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New lung Drug's safety check: how does it mix with existing meds?
Knowledge-focused CompletedThis early-stage trial is testing a new drug called HRS-9813 in 20 healthy volunteers to see how it interacts with two standard treatments for pulmonary fibrosis (lung scarring): pirfenidone and nintedanib. The goal is to measure drug levels in the blood and check for side effect…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Sep 21, 2026 17:00 UTC
-
Healthy volunteers help test new injection method for eczema drug
Knowledge-focused CompletedThis early-stage study tests a new drug called SHR-1819 in 160 healthy adults to see how it enters the body when given with different injection devices. The goal is to compare the drug levels and safety between devices, not to treat any disease. Participants must be 18-55 years o…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
New drug SHR-2106 tested in healthy volunteers – no cure yet
Knowledge-focused CompletedThis early-stage study tested a new drug, SHR-2106, in 52 healthy adults to see if it is safe and how the body processes it. Participants received a single dose either through a vein or under the skin. The goal was not to treat any disease, but to gather important safety informat…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC